ClinicalTrials.gg
Active, not recruitingNCT06517758Updated Aug 12, 2026

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

A Phase 3 interventional study of Iptacopan and Matching Placebo in Generalized Myasthenia Gravis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 116 sites in 18 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Planned enrollment
20th of 108
146 · median 56
Started
2024
with 22 others
Phase 3
45 of 144
9 open now
Primary completion
2027-04
later than 28 of 72 live
Registered
96th of 144
by date
Lead sponsor
3 of 144
Novartis Pharmaceuticals

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 20th largest by planned enrollment of the 108 interventional ones that give a count, is one of 23 that started in 2024, is one of 45 in phase 3, reaches primary completion later than 28 of the 72 other live ones, and was the 96th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG who are on stable SOC treatment. Participants who meet the eligibility criteria will be randomized in a ratio of 1:1, to receive either iptacopan or matching placebo, for 6 months (180 days) while continuing on a stable SOC treatment. The randomization will be stratified based on region.

Read the detailed description

The study consists of a 6-month double-blind treatment period for the primary efficacy and safety analysis followed by a maximum duration of 60 month open label extension period. A safety follow up assessment will be performed, one 7 days after the last administration of study treatment and one 30 days after the last administration of study treatment for all participants.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • Myasthenia Gravis
  • gMG
  • randomized
  • placebo-controlled
  • double-blind
  • phase III
  • AChR+
  • SOC treatment
  • iptacopan
  • LNP023
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with generalized Myasthenia Gravis (age 18-85 years) at screening
  • Positive serology testing for AChR+ antibody at screening
  • Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG at screening and likely not in need of a respirator for the duration of the study, as judged by the Investigator.
  • The confirmation of the diagnosis of gMG should be documented and supported by ≥1 of the following 3 tests:
  • History of abnormal neuromuscular transmission demonstrated by single-fiber electromyography or repetitive nerve stimulation.
  • History of positive test with short-acting acetylcholinesterase inhibitors (e.g. neostigmine or edrophonium chloride)
  • Patient has demonstrated improvement in MG signs on oral acetylcholinesterase inhibitors as assessed by the treating physician.
  • Baseline MG-ADL score ≥6, with ≥50% of the total score due to non-ocular symptoms
  • Participants receiving at least one of the following treatments for gMG for ≥ 6 months prior to baseline;
  • One or more NSISTs or
  • plasmapheresis, plasma exchange, or intravenous immunoglobulin (at least quarterly) to control symptoms despite treatment with and NSISTs; or
  • an approved FcRN antagonist approved for gMG; or
  • rituximab or
  • other approved gMG disease modifying therapies excluding complement inhibitors.
  • Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection is required prior to the start of study treatment. If the participant has not been previously vaccinated, or if a booster was required, the vaccine should be given according to local guidelines at least 2 weeks prior to first study drug administration. If study treatment has to start earlier than 2 weeks post-vaccination, prophylactic antibiotic treatment should be initiated at the start of study treatment and continued until at least 2 weeks after vaccination or booster was completed.

Note: For US sites participating in Study CLNP023Q12301, the completion of the meningococcal vaccination or booster is required for patients with gMG prior to initiating study treatment, irrespective of prophylactic antibiotic use.

Exclusion criteria

Exclusion Criteria:

  • Have been treated with intravenous immunoglobulin (IVIG)/plasma exchange (PLEX) in the past month, with rituximab in the past 6 months, eculizumab in the past 2 months, ravulizumab or other complement inhibitors in the past 3 months, efgartigimod or other anti- FcRn therapies in the past 3 months, or had a thymectomy in the past 6 months or a planned thymectomy during the trial period.
  • Participants with active or chronic uncontrolled bacterial, viral, or fungal infection at screening, including patients who test positive for an active viral infection at screening with: Active Virus (HBV); Active Virus (HCV);

    • (HIV) positive serology associated with an Acquired Immune Deficiency Syndrome (AIDS)-defining condition or with a cluster of differentiation 4 (CD4) count

      • 200 cells/mm3
  • Female participants who are pregnant or lactating, or are intending to become pregnant.
  • Women of , defined as all women physiologically capable of becoming pregnant from menarche until becoming , unless they are using effective methods of during dosing of study treatment and an additional one week following cessation of study treatment. Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., hormonal profile confirming menopause and/or age-appropriate history of vasomotor symptoms).
  • Active systemic bacterial, viral (including COVID-19) or fungal infection or any major episode of infection that required hospitalization or injectable antimicrobial therapy within 14 days prior to study drug administration.
  • History of recurrent invasive infections caused by encapsulated organisms, e.g., N. meningitidis and S. pneumoniae.
  • Presence of fever ≥ 38 °C (100.4 °F) within 7 days prior to study drug administration
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
146 participants (estimated)

Study arms

  • Experimental
    Iptacopan

    Iptacopan orally for 6 months (double-blind) followed by open-label iptacopan for up to 60 months

    Drug: Iptacopan

  • Placebo comparator
    Matching Placebo

    Placebo orally for 6 months (double-blind) followed by open-label iptacopan for up to 60 months

    Other: Matching Placebo

Interventions

  • Hard gelatin capsule

  • OtherMatching Placebo

    Hard gelatin capsule

06

What researchers measure

Primary outcomes

  1. Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living (MG-ADL) total score

    The MG-ADL is an 8 item interviewer led patient reporting scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function. The scores ranges from 0 to 24, with a higher score indicating more disability.

    Time frame: Baseline to Month 6

Secondary outcomes

  1. Change from baseline to Month 6 in Quantitative MG (QMG) total score

    The Quantitative Myasthenia Gravis (QMG) Score is a 13-item direct physician assessment scoring system that quantifies disease severity, based on impairments of body functions and structures. The total QMG score ranges from 0 to 39, where higher scores indicated greater disease severity.

    Time frame: Baseline to Month 6

  2. Proportion of participants with ≥ 5 points reduction from baseline to Month 6 of QMG total score without rescue medication and/or strongly confounding prohibited medication

    The Quantitative Myasthenia Gravis (QMG) Score is a 13-item direct physician assessment scoring system that quantifies disease severity, based on impairments of body functions and structures. The total QMG score ranges from 0 to 39, where higher scores indicated greater disease severity.

    Time frame: Baseline to Month 6

  3. Proportion of participants with ≥ 3 points reduction from baseline to Month 6 of MG-ADL total score without rescue medication and/or strongly confounding prohibited medication

    The MG-ADL is an 8 item patient reporting scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function. The scores ranges from 0 to 24, with a higher score indicating more disability.

    Time frame: Baseline to Month 6

  4. Proportion of participants achieving MSE at Month 6, defined as MG-ADL score of 0 or 1 at Month 6 without rescue therapy and/or strongly confounding prohibited medication

    The MG-ADL is an 8 item interviewer led patient reporting scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function. The scores ranges from 0 to 24, with a higher score indicating more disability.

    Time frame: Baseline to Month 6

  5. Change from baseline to Month 6 in Myasthenia Gravis Composite (MGC) total score

    The MGC is a 10-item instrument that measures the symptoms and signs of MG based on physician examination and patient history. Items relate to ptosis, double vision, eye closure, talking, chewing, swallowing, breathing, neck flexion, shoulder abduction, and hip flexion. Each item is scored on an ordinal scale with 4 possible categories and weighted. The total score ranges from 0 to 50, where higher scores indicate more severe impairments.

    Time frame: Baseline to Month 6

  6. Change from baseline to Month 6 in revised MG Quality of Life Questionnaire (MG-QOL15r) survey score

    The revised MG-QoL15 is a 15-item health related quality of life questionnaire completed by participants, designed to measure quality of life in gMG. Items on the MG-QoL15 relate to physical, social, and psychological components and are scored from 0 (not at all) to 2 (very much). The cumulative scores range from 0 to 30, with higher scores representing worse quality of life and dissatisfaction with MG-related dysfunction.

    Time frame: Baseline to Month 6

  7. Incidence of adverse events

    Any significant and notable changes in clinical laboratory values, vital signs, electrocardiograms and Columbia Suicidal Severity Rating Scale.

    Time frame: Baseline to Month 6

  8. Proportion of time during which participants showed a reduction of ≥ 2 points in MG-ADL total score that was maintained up to Month 6

    The MG-ADL is an 8 item patient reporting scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function. The scores ranges from 0 to 24, with a higher score indicating more disability.

    Time frame: Baseline to Month 6

  9. Proportion of early MG-ADL responders during treatment (early responders with first MG-ADL improvement from baseline of ≥ 2 points occurring by week 4)

    The MG-ADL is an 8 item patient reporting scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function. The scores ranges from 0 to 24, with a higher score indicating more disability.

    Time frame: Baseline to Month 6

  10. Change from baseline to Month 6 in EuroQol-5 Dimensions-5 Level (EQ-5D-5L)

    This questionnaire designed to assess health status in adults. The measure is divided into two distinct sections, the descriptive system and the EQ visual analogue scale (EQ VAS). The first section includes one item addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Participants rate each of these items from 1 of the 5 levels: no problems, slight problems, moderate problems, severe problems, or unable to/extreme. A composite health state is then defined by combining the levels for each dimension into a 5-digit number. The second section includes the EQ visual analogue scale (EQ VAS) that measures self-rated health status utilizing a vertically oriented visual analogue scale where 100 represents the "best imaginable health state" and 0 represents the "worst imaginable health state." Respondents are asked to rate their current health by placing a mark along this continuum.

    Time frame: Baseline to Month 6

  11. Proportion of participants with a reduction of ≥ 3 points from baseline to Month 6 in MGC total score

    The MGC is a 10-item instrument that measures the symptoms and signs of MG based on physician examination and patient history. Items relate to ptosis, double vision, eye closure, talking, chewing, swallowing, breathing, neck flexion, shoulder abduction, and hip flexion. Each item is scored on an ordinal scale with 4 possible categories and weighted. The total score ranges from 0 to 50, where higher scores indicate more severe impairments.

    Time frame: Baseline to month 6

  12. Change from baseline in MG-ADL total score

    The MG-ADL is an 8 item patient reporting scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function. The scores ranges from 0 to 24, with a higher score indicating more disability.

    Time frame: Baseline to Month 66 (end of extension phase)

  13. Proportion of participants achieving a reduction in oral corticosteroids (OCS) dose compared to Core Part that was maintained up to end of Extension Part

    Long-term effect of iptacopan in patients with gMG will be assessed by the proportion of patients that had a reduction in dose or discontinuation of oral corticosteroids, higher proportion would indicate greater long-term effect.

    Time frame: Month 6 (end of core phase) to Month 30 (end of extension phase)

  14. Incidence of adverse events

    Any significant and notable changes in clinical laboratory values, vital signs, electrocardiograms and Columbia Suicidal Severity Rating Scale.

    Time frame: Baseline to Month 30 (end of extension phase)

07

Study locations

116 sites
  • Honor Health Research Institute
    Scottsdale, Arizona 85258, United States
  • Fullerton Neuro and Headache Ctr
    Fullerton, California 92835, United States
  • California Pacific Medical Center
    Sacramento, California 94115, United States
  • Augusta University Georgia
    Augusta, Georgia 30912, United States
  • University of Chicago Medical Centr
    Chicago, Illinois 60637, United States
  • Prairie Heart Institute
    Springfield, Illinois 62769, United States
  • Mid Atlantic Epilepsy and Sleep Ctr
    Bethesda, Maryland 20817-1807, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Penn Presbyterian Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt University Medical CenterX
    Nashville, Tennessee 37221, United States
  • Nerve and Muscle Center of Texas
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1428AQK, Argentina
  • Novartis Investigative Site
    Córdoba, Córdoba Province X5004AOA, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province 2000, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1012AAR, Argentina
  • Novartis Investigative Site
    Caba, C1055AAF, Argentina
  • Novartis Investigative Site
    Caba, C1182, Argentina
  • Novartis Investigative Site
    Capital Federal, C1023AAB, Argentina
  • Novartis Investigative Site
    Córdoba, X5004CDT, Argentina
  • Novartis Investigative Site
    Camperdown, Sydney NSW 2050, Australia
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90560-030, Brazil
  • Novartis Investigative Site
    Joinville, Santa Catarina 89202-165, Brazil
  • Novartis Investigative Site
    Bahia, 40290-000, Brazil
  • Novartis Investigative Site
    São Paulo, 04038-002, Brazil
  • Novartis Investigative Site
    Hefei, Anhui 230001, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510515, China
  • Novartis Investigative Site
    Shenzhen, Guangdong 518053, China
  • Novartis Investigative Site
    Shijiazhuang, Hebei 50030, China
  • Novartis Investigative Site
    Changsha, Hunan 410008, China
  • Novartis Investigative Site
    Suzhou, Jiangsu 215004, China
  • Novartis Investigative Site
    Xi'an, Shaanxi 710075, China
  • Novartis Investigative Site
    Xianyang, Shaanxi 712000, China
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Beijing, 100070, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Fujian, 350001, China
  • Novartis Investigative Site
    Jinan, 250012, China
  • Novartis Investigative Site
    Copenhagen, DK-2100, Denmark
  • Novartis Investigative Site
    Limoges, Haute Vienne 87000, France
  • Novartis Investigative Site
    Garches, 92380, France
  • Novartis Investigative Site
    Nice, 06000, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Paris, 75940, France
  • Novartis Investigative Site
    Munich, Bavaria 81675, Germany
  • Novartis Investigative Site
    Regensburg, Bavaria 93053, Germany
  • Novartis Investigative Site
    Würzburg, Bavaria 97070, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60590, Germany
  • Novartis Investigative Site
    Bochum, 44789, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Athens, 115 28, Greece
  • Novartis Investigative Site
    Chaïdári, 124 62, Greece
  • Novartis Investigative Site
    Larissa, 411 10, Greece
  • Novartis Investigative Site
    Thessaloniki, 54636, Greece
  • Novartis Investigative Site
    Haifa, 3109601, Israel
  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
  • Novartis Investigative Site
    Bologna, BO 40139, Italy
  • Novartis Investigative Site
    Florence, FI 50134, Italy
  • Novartis Investigative Site
    Genova, GE 16132, Italy
  • Novartis Investigative Site
    Milan, MI 20133, Italy
  • Novartis Investigative Site
    Palermo, PA 90127, Italy
  • Novartis Investigative Site
    Palermo, PA 90146, Italy
  • Novartis Investigative Site
    Roma, RM 00133, Italy
  • Novartis Investigative Site
    Roma, RM 00135, Italy
  • Novartis Investigative Site
    Roma, RM 00189, Italy
  • Novartis Investigative Site
    Orbassano, TO 10043, Italy
  • Novartis Investigative Site
    Chiba, Chiba 2608677, Japan
  • Novartis Investigative Site
    Narita, Chiba 286-8520, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 0630005, Japan
  • Novartis Investigative Site
    Nishinomiya, Hyōgo 6638501, Japan
  • Novartis Investigative Site
    Hanamaki, Iwate 0250082, Japan
  • Novartis Investigative Site
    Sendai, Miyagi 9838520, Japan
  • Novartis Investigative Site
    Suita, Osaka 5650871, Japan
  • Novartis Investigative Site
    Higashi-Matsuyama, Saitama 355-0005, Japan
  • Novartis Investigative Site
    Shinjuku Ku, Tokyo 160-0023, Japan
  • Novartis Investigative Site
    Fukuoka, 8128582, Japan
  • Novartis Investigative Site
    Fukushima, 9601295, Japan
  • Novartis Investigative Site
    Hiroshima, 7348551, Japan
  • Novartis Investigative Site
    Lublin, Lublin Voivodeship 20-064, Poland
  • Novartis Investigative Site
    Warsaw, Masovian Voivodeship 02-676, Poland
  • Novartis Investigative Site
    Krakow, POL 31-505, Poland
  • Novartis Investigative Site
    Katowice, Silesian Voivodeship 40-650, Poland
  • Novartis Investigative Site
    Bydgoszcz, 85-065, Poland
  • Novartis Investigative Site
    Katowice, 40-689, Poland
  • Novartis Investigative Site
    Krakow, 31-870, Poland
  • Novartis Investigative Site
    Lublin, 20-410, Poland
  • Novartis Investigative Site
    Poznan, 61-731, Poland
  • Novartis Investigative Site
    Rzeszów, 35-055, Poland
  • Novartis Investigative Site
    Warsaw, 01-684, Poland
  • Novartis Investigative Site
    Lisbon, 1349-019, Portugal
  • Novartis Investigative Site
    Lisbon, 1649-035, Portugal
  • Novartis Investigative Site
    Porto, 4099-001, Portugal
  • Novartis Investigative Site
    Vila Nova de Gaia, 4434-502, Portugal
  • Novartis Investigative Site
    Belgrade, 11000, Serbia
  • Novartis Investigative Site
    Niš, 18108, Serbia
  • Novartis Investigative Site
    Daegu, 41404, South Korea
  • Novartis Investigative Site
    Gwangju, 61469, South Korea

Showing the first 100 of 116 sites across 18 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Apr 2027, 32 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's planned 32 months is above that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2024
First posted
Jul 24, 2024
StartActual
Jul 31, 2024
Primary completionEst.
Apr 30, 2027
CompletionEst.
May 27, 2032
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06517758
Responsible party
Sponsor
First posted
Jul 24, 2024
Start date
Jul 31, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
May 27, 2032 (estimated)
Last update
Aug 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iptacopan

Start the discussion